Swift Medical | March 03, 2022
Swift Medical, the global leader in digital wound care technology, unveiled the Swift Ray 1, a groundbreaking hardware device that wirelessly attaches to a smartphone camera and captures comprehensive clinical data to better support assessment, treatment and monitoring of skin and wound conditions. The Swift Ray 1 fits in the palm of a clinician or patient’s hand, making powerful medical imaging accessible anywhere, from the hospital to the home. Further, this advanced imaging enables the capture of accurate clinical data for every patient, regardless of skin tone, making wound care more equitable for everyone.
“The future of wound care goes beyond what the naked eye can perceive and beyond the walls of the clinic, which is why our dream has always been to equalize and improve healthcare access for humanity through intelligent diagnostics. The Swift Ray 1 gets us one step closer by helping clinicians and patients see below the surface of the skin, to heal wounds faster or prevent them from ever even developing.”
Carlo Perez, co-founder and CEO of Swift Medical
The Swift Ray 1 captures and analyzes important physiological characteristics of wounds that can indicate causes for concern and/or improper healing, such as signs of infection, bacterial colonization, tissue compromise, perfusion, inflammation and blood oxygen levels. The new device illuminates these invisible, beneath-the-skin characteristics through long-wave infrared, near infrared, ultraviolet and enhanced RGB imaging technology - enabling powerful clinical workflows.
The Swift Ray 1 works seamlessly with Swift Medical’s proprietary wound management software application and provides clinicians with unparalleled insights into a patient’s wound healing, informing clinical and operational decision-making. It also integrates directly into many of the leading EHRs to help clinicians both improve clinical efficiency and ensure that all relevant medical information is recorded in the patient’s chart.
“The technology can fit in your pocket. That means it can go anywhere a doctor or nurse goes. It means it’s on them, whenever they need it, wherever their patients are,” said Mike Comer, Founder and CEO at Wound Care Advantage. “There’s no forgetting it on the shelf or fumbling around with wires and clunky imaging devices. You just take it from your pocket and snap a photo. It really does make wound care accessible anywhere.”
Chronic wounds are one of the biggest public health challenges worldwide, and are often associated with other prevalent chronic conditions, such as diabetes and hypertension. More than 8.2 million patients are currently suffering from chronic wounds in North America. As rates of obesity, diabetes and other chronic conditions continue to skyrocket, the number of patients at risk of developing wounds will continue to rise.
The challenges of providing wound care are exacerbated by the reality that high quality care traditionally requires highly trained clinicians using multiple pieces of bulky, expensive equipment in an institutional setting. Conversely, the Swift Ray 1 allows any clinician to capture and share images at any bedside, enabling healthcare organizations to provide more accessible, efficient and preventive care.
The Swift Ray 1 supports a variety of use cases, including early detection of deep tissue injuries and prevention of pressure injuries; identification of wound infections and inhibited wound healing; and remote physiological monitoring of chronic wound patients in the home. The Swift Ray 1 is also ideal for pharmaceutical companies and clinical research organizations engaged in clinical trials.
About Swift Medical
Swift Medical is the global leader in digital wound care. Our mission is to make empathy driven wound care ubiquitous through AI-powered diagnostic technology. We are the trusted wound technology partner of more than 4,100 healthcare facilities in North America across the continuum of care. Our solutions empower healthcare providers to deliver standardized, accessible and equitable wound care for every patient - with advanced, high-precision imaging, compliant documentation, clinical analytics and remote care.
FUTURE OF HEALTHCARE
MedX Health Corp. | November 22, 2021
MedX Health Corp. (“MedX” or the “Company”) and Al Zahrawi Medical Supplies LLC ("Al Zahrawi") are pleased to announce a Memorandum of Understanding between the companies on a two-phase commercialization pilot and distribution agreement for MedX’s leading-edge DermSecure® Screening Platform at select United Arab Emirates (“UAE”) oncology and dermatology clinics beginning this month.
The three-month pilot will involve an estimated 1,000 patients at four dermatology and oncology clinics in Abu Dhabi and Dubai. Upon the successful completion of the two phases, the MedX DermSecure® Screening Platform will become more widely available at clinics and health care facilities across the UAE. As the largest distributor of medical devices in the Gulf Cooperation Council (GCC) region, the partnership with Al Zahrawi positions MedX for continued growth in other Middle Eastern markets including Saudi Arabia, Qatar, Oman, and Bahrain. This initiative is the latest in a series of commercialization pilots recently launched in Europe and the Middle East as part of MedX’s global commercialization strategy, building on pilots underway in the Netherlands, Italy and Turkey. Additional commercialization pilots are anticipated in the coming months.
“At Zahrawi, we are passionate about providing the highest quality products and services to healthcare facilities and laboratories across the GCC,” said David Fawzy Yassa, Business Development Director at Al Zahrawi. “MedX’s teledermatology platform meets these high standards, with a proven ability to improve outcomes for dermatology patients. We’re eager to work with MedX to bring the platform to more patients across the UAE market and other GCC nations.”
Teledermatology is a subspeciality of dermatology that offers safe and effective virtual care – patient screening and assessment – eliminating the need for in-person appointments with a dermatologist. Unlike other teledermatology screening tools available, MedX’s DermSecure® Screening Platform features high-resolution image capture technology for moles, lesions and other skin conditions, providing a complete, virtual dermatological assessment by a certified dermatologist within just 72 hours.
MedX’s leading telemedicine platform allows health-care practitioners to quickly and accurately assess suspicious moles, lesions and other skin conditions via its image capture technology, SIAscopy®, and its secure, cloud-based patient management system, DermSecure®, which transmits and stores patient data throughout the assessment process. MedX’s SIAscopy® is the only technology that captures five images, including four spectrophotometric images 2mm below the skin’s surface.
“This pilot is a significant step forward in growing MedX’s global presence, particularly among countries in the GCC region. During this time of rapid growth for our company, we look forward to working with trusted partners like Al Zahrawi to expand our global footprint and improve more patient outcomes.”
Sylvain Desjeans, MedX CEO
Naman Demaghlatrous, MedX Managing Director of Europe, Middle East and Africa, added, “Our pilot in the UAE is an important foothold in the GCC region – it represents the first of six markets we want to penetrate in the Middle East. Following the successful completion of this UAE pilot, we’ll be seeking other similar opportunities in Saudi Arabia and other GCC nations in the months ahead.”
According to Omnia Health, melanoma skin cancer is of growing concern in the UAE as one of the most common malignancies in men, with an incidence rate of 14.5%.1 The World Health Organization estimates that cancer rates in the Middle East will double by 2030.2 Early and rapid detection of melanoma is key to improving patient outcomes.
About MedX Health Corp
MedX, headquartered in Ontario, Canada, is a leading medical device and software company focused on skin health with its SIAscopy® on DermSecure® telemedicine platform, utilizing its SIAscopy® technology. SIAscopy® is also imbedded in its products SIAMETRICS®, SIMSYS®, and MoleMate®, which MedX manufactures in its ISO 13485 certified facility. SIAMETRICS®, SIMSYS®, and MoleMate® include hand-held devices that use patented technology utilizing light and its remittance to view up to 2 mm beneath suspicious moles and lesions in a pain free, non-invasive manner, with its software then creating real-time images for physicians and dermatologists to evaluate all types of moles or lesions within seconds. These products are cleared by Health Canada, the U.S. Food and Drug Administration, the Therapeutic Goods Administration and Conformité Européenne for use in Canada, the US, Australia, New Zealand, the European Union, Brazil and Turkey.
About Al Zahrawi Medical Supplies LLC
Zahrawi Group is a leading company dedicated to contributing to the UAE, KSA, Qatar, Bahrain and Oman markets by supplying high-quality products and services to hospitals, clinics, laboratories and analytical industries. Zahrawi Group is continuously expanding, progressing and contributing to the prosperity of the people and economy of the region. Zahrawi Group represents an extensive profile of internationally renowned Healthcare and Laboratory manufacturers, such as Medtronic, Agilent Technologies, Dako, Sakura, BD, Sysmex, Cepheid, Hitachi, Sebia and many others. Zahrawi Group continues to show sustainable growth year over year with Dhs 583 Million in revenues in 2020.
Fiercehealthcare | May 13, 2019
Issues such as the opioid epidemic and an increased suicide rate in the U.S. are increasing demand for behavioral health care services even as challenges such as workforce shortages and payment policies are restricting patient access.But policy changes such as improved reimbursement could help the nation's hospitals better address those access issues, according to a new analysis from the American Hospital Association.While nearly one in five Americans is affected by a behavioral health disorder, many individuals are unable to access the services they need," the authors of the report wrote. "Hospitals and health systems play a central role in meeting the health needs of their community.